Was Jonathan Gillis’s MapLight Therapeutics (MPLT) share sale made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Jonathan Gillis on December 26, 2025. Such plans pre-schedule trades, indicating these sales were planned rather than timed discretionarily.

MapLight CAAO sells 69,835 shares in plan

MapLight Therapeutics CAAO and PAO Jonathan Gillis reported open-market sales of 69,835 shares of Voting Common Stock.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics CAAO and PAO Jonathan Gillis reported open-market sales of 69,835 shares of Voting Common Stock. The transactions occurred on April 27–28, 2026, across five sales at weighted average prices such as $28.94 and $30.83 per share. All sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025, and he continues to hold a direct equity position reported in the filing.

Insider Trade Summary 10b5-1

Net Seller: 69,835 shares

Net Sell 5 txns

Insider GILLIS JONATHAN

Role CAAO and PAO

Sold 69,835 shs ($2.09M)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	17,235	$30.33	$523K
Sale	Voting Common Stock	700	$30.83	$22K
Sale	Voting Common Stock	7,914	$28.94	$229K
Sale	Voting Common Stock	29,623	$29.60	$877K
Sale	Voting Common Stock	14,363	$30.46	$437K

Holdings After Transaction: Voting Common Stock — 181,219 shares (Direct)

Footnotes (6)

F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.27 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.755 to $30.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.81 to $30.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 69,835 shares Number of sale transactions: 5 transactions Example sale price: $28.94 per share +3 more

6 metrics

Shares sold 69,835 shares Total Voting Common Stock sold across all reported transactions

Number of sale transactions 5 transactions Open-market sales on April 27–28, 2026

Example sale price $28.94 per share Weighted average price for one reported sale of Voting Common Stock

Example sale price $30.83 per share Weighted average price for one reported sale of Voting Common Stock

Trading plan adoption date December 26, 2025 Date Jonathan Gillis adopted the Rule 10b5-1 trading plan

Sell transactions count 5 sales SellCount in transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Voting Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Voting Common Stock financial

"security_title: Voting Common Stock"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MapLight Therapeutics (MPLT) report for Jonathan Gillis?

MapLight Therapeutics reported that CAAO and PAO Jonathan Gillis sold 69,835 shares of Voting Common Stock in five open-market transactions on April 27–28, 2026. These trades were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 26, 2025.

Over what dates did Jonathan Gillis sell MapLight Therapeutics (MPLT) shares?

Jonathan Gillis sold MapLight Therapeutics shares over two days, April 27 and April 28, 2026. The Form 4 lists five separate open-market sales of Voting Common Stock during this period, all conducted under a previously adopted Rule 10b5-1 trading plan.

How many MapLight Therapeutics (MPLT) shares did Jonathan Gillis sell in total?

According to the Form 4, Jonathan Gillis sold a total of 69,835 shares of MapLight Therapeutics Voting Common Stock. This total comes from five individual open-market sale transactions reported in the filing’s transaction summary for those two trading days.

At what prices did Jonathan Gillis sell his MapLight Therapeutics (MPLT) shares?

The filing reports weighted average sale prices, with individual transactions showing prices such as $28.94, $29.60, $30.33, $30.46 and $30.83 per share. Footnotes note that each reported price reflects multiple trades within specified intraday price ranges.

What is Jonathan Gillis’s role at MapLight Therapeutics (MPLT) in this Form 4?

The Form 4 identifies Jonathan Gillis as an officer of MapLight Therapeutics, serving as CAAO and PAO. The reported transactions involve his direct holdings of Voting Common Stock, as indicated by the direct ownership code in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/29/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS JONATHAN

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CAAO and PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	04/27/2026		S⁽¹⁾		7,914	D	$28.94⁽²⁾	243,140	D
Voting Common Stock	04/27/2026		S⁽¹⁾		29,623	D	$29.6⁽³⁾	213,517	D
Voting Common Stock	04/27/2026		S⁽¹⁾		14,363	D	$30.46⁽⁴⁾	199,154	D
Voting Common Stock	04/28/2026		S⁽¹⁾		17,235	D	$30.33⁽⁵⁾	181,919	D
Voting Common Stock	04/28/2026		S⁽¹⁾		700	D	$30.83⁽⁶⁾	181,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.27 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.27 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.755 to $30.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.81 to $30.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR